Drug Discovery Featured Articles & Applications

  1. Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx 6/5/2026

    DDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.

  2. Discovery Dialogues: Stef van Grieken, CEO, Cradle Bio 6/5/2026

    DDO caught up with Stef van Grieken, CEO of Cradle Bio, which uses AI to speed protein design, putting tools in scientists’ hands. Gains in lead optimization are clear, but safety CMC and tough targets remain key challenges.

  3. Discovery Dialogues: Helen Bright, Ph.D., CSO of Centauri Tx 6/4/2026

    At PEGS Boston, Helen Bright, PhD explained how Centauri’s CTX187 harnesses innate immunity to fight resistant gram-negative infections and support better outcomes.

  4. Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort 6/3/2026

    Nucleate Boston’s 2026 Activator shows how mentorship, structure, and community can help promising young scientists become credible biotech founders.

  5. FDA's New Oncology Guidance Signals The Next Phase Of Drug Development Reform 6/2/2026

    New FDA guidance encourages streamlined nonclinical safety assessments for certain cancer therapies and explicitly seeks to reduce unnecessary animal testing while maintaining patient safety.

  6. DDW 2026 Signalled The Next Era Of Competitive Landscape In IBD 6/2/2026

    At the DDW 2026 meeting, the IBD landscape was portrayed as increasingly competitive and diversified, with emerging players and novel mechanisms challenging established standards of care.

  7. Why Tolerability Will Drive The Next Wave Of Obesity Treatments 5/29/2026

    For the next generation of obesity medicines, enhancing how patients experience therapy will inform discovery and development efforts and may ultimately determine long-term success.

  8. What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing 5/28/2026

    RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.

  9. Synaptic Regeneration And The Future Of Alzheimer's R&D 5/22/2026

    For too long, treating Alzheimer’s disease has been a case of “managed decline.” We need to move beyond slowing disease progression toward achieving tangible functional recovery.

  10. Oncology Drug Discovery Is Targeting The Wrong Problem 5/21/2026

    There is a growing tension between what we measure and what ultimately matters. This disconnect raises an uncomfortable but necessary question: are we targeting the right problem?